UPDATE: Canaccord Genuity Initiates Coverage on Regeneron Pharmaceuticals on Expected Continued Pipeline Success

By: via Benzinga
In a report published Wednesday, Canaccord Genuity analyst John Newman initiated coverage on Regeneron Pharmaceuticals (NASDAQ: REGN) ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.